Precision Health Informatics and Concerto HealthAI to Collaborate on Advanced Precision Medicine Solutions

▤ Summary

Concerto HealthAI, the market leader for Real-World Data (RWD) and enterprise AI technology, announced today an agreement with Precision Health Informatics, a subsidiary of community-based cancer care pioneer Texas Oncology, to accelerate the advancement of precision medicine to treat cancer patients. Precision Health Informatics will work with Concerto HealthAI to advance RWD solutions, research studies, and AI-enabled technologies – focusing on genomic and molecular characterization of patient disease to develop effective new therapies to treat some of the most challenging and devastating cancers. Precision Health Informatics joins an expanding set of Concerto HealthAI’s Real-World Evidence collaborators, such as theAmerican Society of Clinical Oncology’s CancerLinQ® relationship announced in late 2017. “Concerto HealthAI’s deep expertise in research-grade RWD solutions and AI technologies make it the ideal collaborator with Precision Health Informatics to help us more quickly develop medical innovations that benefit patients in our practice and elsewhere.” “At Concerto HealthAI, we seek clinical collaborators committed to advancing insights and new treatment strategies for patients with the highest unmet medical needs,” said Jeff Elton, PhD, CEO of Concerto HealthAI. “Precision Health Informatics is making a deep commitment to enabling precision medicine, which we see as highly complementary to the work of our biomedical innovator partners.” This collaboration will advance novel research solutions, integrating deep clinical insights derived from electronic medical record data, particularly information about the molecular basis of disease derived from tissue or liquid samples.

▦ Linked Companies

ConcertAI

$250M to $500M